Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors*

Presenilins are integral membrane protein involved in the production of amyloid β-protein. Mutations of the presenilin-1 and -2 gene are associated with familial Alzheimer's disease and are thought to alter γ-secretase cleavage of the β-amyloid precursor protein, leading to increased production of longer and more amyloidogenic forms of Aβ, the 4-kDa β-peptide. Here, we show that radiolabeled γ-secretase inhibitors bind to mammalian cell membranes, and a benzophenone analog specifically photocross-links three major membrane polypeptides. A positive correlation is observed among these compounds for inhibition of cellular Aβ formation, inhibition of membrane binding and cross-linking. Immunological techniques establish N- and C-terminal fragments of presenilin-1 as specifically cross-linked polypeptides. Furthermore, binding of γ-secretase inhibitors to embryonic membranes derived from presenilin-1 knockout embryos is reduced in a gene dose-dependent manner. In addition, C-terminal fragments of presenilin-2 are specifically cross-linked. Taken together, these results indicate that potent and selective γ-secretase inhibitors block Aβ formation by binding to presenilin-1 and -2.

[1]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[2]  P. Beckett,et al.  A Short Diastereoselective Synthesis of 2,3-Disubstituted Succinates , 1993 .

[3]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[4]  C. Czech,et al.  Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms , 2000, Progress in Neurobiology.

[5]  Sarah Tomlin,et al.  Microtechnology: Laying it on thick , 1999, Nature.

[6]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[8]  B. Strooper,et al.  The presenilins in Alzheimer's disease--proteolysis holds the key. , 1999, Science.

[9]  B. Strooper,et al.  Alzheimer's disease: A firm base for drug development , 1999, Nature.

[10]  H. Vanderstichele,et al.  Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[12]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[13]  D. Selkoe,et al.  The Proteolytic Fragments of the Alzheimer’s Disease-associated Presenilin-1 Form Heterodimers and Occur as a 100–150-kDa Molecular Mass Complex* , 1998, The Journal of Biological Chemistry.

[14]  N. Hooper,et al.  Membrane protein secretases. , 1997, The Biochemical journal.

[15]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[16]  P. Fraser,et al.  The Presenilin 1 Protein Is a Component of a High Molecular Weight Intracellular Complex That Contains β-Catenin* , 1998, The Journal of Biological Chemistry.

[17]  P. Harden,et al.  A combinatorial approach to the identification of dipeptide aldehyde inhibitors of beta-amyloid production. , 1999, Journal of medicinal chemistry.

[18]  S. Lincoln,et al.  A Loss of Function Mutation of Presenilin-2 Interferes with Amyloid β-Peptide Production and Notch Signaling* , 1999, The Journal of Biological Chemistry.

[19]  C. Haass Presenilins: Genes for Life and Death , 1997, Neuron.

[20]  E. Harlow,et al.  Using Antibodies: A Laboratory Manual , 1999 .

[21]  M. Wolfe,et al.  Inhibition of β-amyloid formation as a therapeutic strategy , 1999 .